Influence of Newly Synthesized Cholesterol on Bile Acid Synthesis During Chronic Inhibition of Bile Acid Absorption

The effects of newly synthesized cholesterol availability on bile acid synthesis are largely unknown, particularly in humans. The present study was aimed to study the changes induced on bile acid synthesis by simvastatin, a competitive inhibitor of hydroxymethyl glutaryl–CoA (HMG–CoA) reductase, the rate–limiting enzyme of cholesterol synthesis, during pharmacologic interruption of the enterohepatic circulation. Six patients with primary hypercholesterolemia were studied in basal conditions, after treatment with the bile acid binding resin cholestyramine alone (8–16 g/d for 6-8 weeks) and subsequently in combination with simvastatin (40 mg/d for 6-8 weeks). Cholesterol 7α–hydroxylation rate, a measure of total bile acid synthesis, was assayed in vivo by tritium release analysis. Serum lathosterol levels were assayed by gas chromatography—mass spectrometry as a measure of cholesterol synthesis. Serum total and low–density lipoprotein–cholesterol were reduced significantly after cholestyramine (by 26% and 30%, respectively) and during combined treatment (by 47% and 55%). 7α–Hydroxylation rates increased nearly 4–fold with cholestyramine alone; addition of simvastatin induced a significant decrease of hydroxylation rates (cholestyramine alone, 1,591 ± 183 mg/d; plus simvastatin, 1,098 ± 232 mg/d; mean ± SEM; P < .05). Hydroxylation rates significantly correlated with serum lathosterol/cholesterol ratio ( r = 0.79, P < .05). In conclusion, in conditions of chronic stimulation bile acid synthesis may be affected by changes in newly synthesized cholesterol availability. The finding might relate to the degree of substrate saturation of microsomal cholesterol 7α–hydroxylase; alternatively, newly synthesized cholesterol might induce a stimulatory effect on cholesterol 7α–hydroxylase transcription. (Hepatology 2003;38:939–946).